SCHEMBL17522927

SCHEMBL17522927

O=c1ccc(B(O)O)cn1CC1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.33
DPP7 Q9UHL4 1/20 0.33
BMPR1A P36894 1/20 0.33
ACVRL1 P37023 1/20 0.33
ACVR1 Q04771 1/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
PDE10A Q9Y233 1/20 0.31
DRD2 P14416 1/20 0.31
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
HTR2B P41595 1/20 0.31
SIGMAR1 Q99720 1/20 0.31
ICMT O60725 1/20 0.30
GRIA2 P42262 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17643854 0.75 LPL (0.41) CA1CA2KDM4EALDH1A1POLB
SCHEMBL23950391 0.74 PIK3CD (0.37) DPP4DPP7BMPR1AACVRL1ACVR1
SCHEMBL17120437 0.74 ALDH1A1 (0.51) DPP4DPP7BMPR1AACVRL1ACVR1
SCHEMBL120724 0.74 HTR7 (0.39) BMPR1AACVRL1ACVR1CA12CA1
SCHEMBL23950575 0.73 ADORA2B (0.38) DPP4DPP7BMPR1AACVRL1ACVR1
SCHEMBL29951297 0.70 CA12 (0.44) CA12CA1CA2CA9
SCHEMBL21350503 0.70 MAPT (0.48) DPP4DPP7BMPR1AACVRL1ACVR1
SCHEMBL29079038 0.70 PI4KA (0.38) GRIA2GRIN2APIK3CDPIK3CAPI4KA
SCHEMBL13875960 0.69 DPP4 (0.37) DPP4DPP7BMPR1AACVRL1ACVR1
SCHEMBL15719392 0.69 SIGMAR1 (0.49) SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9562033-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2017-02-07 US disclosed
US-9562033-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2017-02-07 US disclosed
US-20160039783-A1 Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses HIVIH (FR) 2016-02-11 US disclosed
US-20160039783-A1 Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses HIVIH (FR) 2016-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039783-A1 Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses POLRMT, MAVS, EIF2AK2 DPP4 667/4885DPP7 975/4885BMPR1A 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.